RxDoctor Payments Data

Jose Casanova, MD

Neurology · Canton, OHNPI 1851325542

Payments from drug & device makers

$2,297in general payments, 2019–2025

Across 176 payments — averaging $13.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$290
  • Biohaven Pharmaceuticals, Inc.$245
  • AstraZeneca$226
  • Amgen$224
  • Teva Pharmaceuticals USA, Inc.$201
  • Johnson & Johnson$186
  • plus $924 from 18 others

What the payments were for

  • Food & beverage$2,11992%
  • Education$1788%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,297 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$253,794
Medicare patients
251
Services billed
35,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate82$83,451
Ajovy AutoinjectorFremanezumab-Vfrm51$53,173
KevzaraSarilumab12$48,990
Emgality PenGalcanezumab-Gnlm33$31,774
UbrelvyUbrogepant27$30,795
QuliptaAtogepant22$25,142
ImitrexSumatriptan Succinate11$11,952
Sumatriptan Succinate76$5,252
Carbamazepine ErCarbamazepine22$3,050
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen88$2,757
Levetiracetam91$2,230
Oxycodone Hcl71$2,220
Lidocaine31$2,182
Primidone84$1,969
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen71$1,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$90$83,45182 claims
AbbVieUbrelvy, Qulipta$290$55,93749 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 702 neurology providers in Ohio.

Other neurology in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →